Barclays Miami: MannKind CEO Michael Castagna shares an update on the company, including a recent $360M acquisition, and two regulatory reviews at FDA that have decision dates over the coming months
- Mar 11
- 1 min read
He describes learnings from Afrezza's commercialization, why the company acquired scPharmaceuticals, an update on their partnership with United Therapeutics in PAH, and a key IPF asset that is in the pipeline.
.png){kind=logo}